Spatiotemporal Delivery Strategies for Promoting Musculoskeletal Tissue Regeneration

A primary regenerative medicine strategy is to stimulate or augment endogenous repair mechanisms that promote functional restoration of damaged or degenerated tissues. There is increasing evidence that maximizing the potency of tissue regenerative therapies will require design and development of delivery approaches that provide controlled spatiotemporal release of key signaling molecules. Guidance on which factors to deliver and the timing of delivery is emerging from advances in understanding of critical pathways involved in the development of integrated musculoskeletal tissues. A broad range of biomaterials‐based deployment technologies are becoming available that allow controlled spatial presentation and release kinetics of biological cues. The purpose of this perspective article is to review promising spatiotemporal delivery strategies designed to promote functional tissue regeneration with an emphasis on vascularized bone repair.

[1]  David J Mooney,et al.  Quantitative assessment of scaffold and growth factor‐mediated repair of critically sized bone defects , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[2]  J M Polak,et al.  Scaffolds and biomaterials for tissue engineering: a review of clinical applications. , 2003, Clinical otolaryngology and allied sciences.

[3]  Robert E Guldberg,et al.  Sustained release of BMP-2 in a lipid-based microtube vehicle. , 2009, Acta biomaterialia.

[4]  Linda G Griffith,et al.  Engineering principles of clinical cell-based tissue engineering. , 2004, The Journal of bone and joint surgery. American volume.

[5]  Jay R Lieberman,et al.  The role of growth factors in the repair of bone. Biology and clinical applications. , 2002, The Journal of bone and joint surgery. American volume.

[6]  C. T. Wagner,et al.  Evaluation criteria for musculoskeletal and craniofacial tissue engineering constructs: a conference report. , 2008, Tissue engineering. Part A.

[7]  Ana Jaklenec,et al.  Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. , 2008, Tissue engineering. Part A.

[8]  W. Hayes,et al.  Bone regeneration by implantation of purified, culture‐expanded human mesenchymal stem cells , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[9]  K. Anseth,et al.  Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. , 2005, Acta biomaterialia.

[10]  Anna Spagnoli,et al.  Regenerative Effects of Transplanted Mesenchymal Stem Cells in Fracture Healing , 2009, Stem cells.

[11]  A C Masquelet,et al.  Induced membranes secrete growth factors including vascular and osteoinductive factors and could stimulate bone regeneration , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[12]  V. Goldberg,et al.  The Effect of Implants Loaded with Autologous Mesenchymal Stem Cells on the Healing of Canine Segmental Bone Defects* , 1998, The Journal of bone and joint surgery. American volume.

[13]  S. Bhang,et al.  Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. , 2008, Biochemical and biophysical research communications.

[14]  H. Terai,et al.  Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2). , 2006, Biomaterials.

[15]  Yinghua Su,et al.  VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  David J Mooney,et al.  Designing scaffolds to enhance transplanted myoblast survival and migration. , 2006, Tissue engineering.

[17]  M. Gebhardt,et al.  Fractures of allografts. Frequency, treatment, and end-results. , 1990, The Journal of bone and joint surgery. American volume.

[18]  M. Bostrom,et al.  Potential Role of Bone Morphogenetic Proteins in Fracture Healing , 1998, Clinical orthopaedics and related research.

[19]  R. Guldberg,et al.  Biological effects of rAAV-caAlk2 coating on structural allograft healing. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Eben Alsberg,et al.  Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. , 2004, Bone.

[21]  A. Woolf,et al.  Burden of major musculoskeletal conditions. , 2003, Bulletin of the World Health Organization.

[22]  D. Biau,et al.  Case Report: Reconstruction of a 16-cm Diaphyseal Defect after Ewing’s Resection in a Child , 2009, Clinical orthopaedics and related research.

[23]  Sha Huang,et al.  Release of bioactive BMP from dextran-derived microspheres: a novel delivery concept. , 2006, International journal of pharmaceutics.

[24]  T. Clemens,et al.  Activation of the hypoxia-inducible factor-1α pathway accelerates bone regeneration , 2008, Proceedings of the National Academy of Sciences.

[25]  Richard Tuli,et al.  Human mesenchymal progenitor cell-based tissue engineering of a single-unit osteochondral construct. , 2004, Tissue engineering.

[26]  Robert M Nerem,et al.  Tissue engineering: the hope, the hype, and the future. , 2006, Tissue engineering.

[27]  Chao Wan,et al.  Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[28]  Peter Carmeliet,et al.  Blood vessels and nerves: common signals, pathways and diseases , 2003, Nature Reviews Genetics.

[29]  Chao Wan,et al.  The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. , 2007, The Journal of clinical investigation.

[30]  Jueren Lou,et al.  Evaluation of different scaffolds for BMP-2 genetic orthopedic tissue engineering. , 2005, Journal of biomedical materials research. Part B, Applied biomaterials.

[31]  Robert E Guldberg,et al.  Combination of platelet-rich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair. , 2007, Journal of biomedical materials research. Part A.

[32]  Robert E Guldberg,et al.  Recent advances in gene delivery for structural bone allografts. , 2007, Tissue engineering.

[33]  A. Day,et al.  Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. , 2009, JAMA.

[34]  D. Mooney,et al.  Combined Angiogenic and Osteogenic Factor Delivery Enhances Bone Marrow Stromal Cell‐Driven Bone Regeneration , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Timothy A. Miller,et al.  BMP-2 exerts differential effects on differentiation of rabbit bone marrow stromal cells grown in two-dimensional and three-dimensional systems and is required for in vitro bone formation in a PLGA scaffold. , 2004, Experimental cell research.

[36]  Bin Wang,et al.  Activation of demineralized bone matrix by genetically engineered human bone morphogenetic protein-2 with a collagen binding domain derived from von Willebrand factor propolypeptide. , 2007, Journal of biomedical materials research. Part A.

[37]  R. Bellamkonda,et al.  Lipid-based microtubular drug delivery vehicles. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Ann Sandison,et al.  Comparison of the healing of open tibial fractures covered with either muscle or fasciocutaneous tissue in a murine model , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[39]  L. Claes,et al.  Moderate soft tissue trauma delays new bone formation only in the early phase of fracture healing , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[40]  M. Swiontkowski,et al.  Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. , 2006, The Journal of bone and joint surgery. American volume.

[41]  A. Reddi Bone and cartilage differentiation. , 1994, Current opinion in genetics & development.

[42]  O. Reikerås,et al.  Influence of Extensive Muscle Injury on Fracture Healing in Rat Tibia , 2003, Journal of orthopaedic trauma.

[43]  R. Cancedda,et al.  Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. , 2000, Journal of cell science.

[44]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[45]  R. Guldberg,et al.  Periosteal Progenitor Cell Fate in Segmental Cortical Bone Graft Transplantations: Implications for Functional Tissue Engineering , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  S. J. Lee Cytokine delivery and tissue engineering. , 2000, Yonsei medical journal.

[47]  Hiromu Ito,et al.  Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy , 2005, Nature Medicine.

[48]  Robert E Guldberg,et al.  Noninvasive image analysis of 3D construct mineralization in a perfusion bioreactor. , 2007, Biomaterials.

[49]  L. Nordsletten Recent developments in the use of bone morphogenetic protein in orthopaedic trauma surgery , 2006, Current medical research and opinion.

[50]  A. Masquelet,et al.  Muscle reconstruction in reconstructive surgery: soft tissue repair and long bone reconstruction , 2003, Langenbeck's Archives of Surgery.

[51]  C. Laurencin,et al.  Bone tissue engineering by gene delivery. , 2006, Advanced drug delivery reviews.

[52]  K. Lyons,et al.  Bone morphogenetic protein-2: biology and applications. , 1996, Clinical orthopaedics and related research.

[53]  D. Stewart,et al.  Effect of cell‐based VEGF gene therapy on healing of a segmental bone defect , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[54]  D J Mooney,et al.  Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis , 2007, Journal of thrombosis and haemostasis : JTH.

[55]  H. Redmond,et al.  Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Michael J Yaszemski,et al.  Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. , 2009, Biomaterials.

[57]  S D Cook,et al.  Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. , 1995, The Journal of bone and joint surgery. American volume.

[58]  Franz E Weber,et al.  Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. , 2005, Biotechnology and bioengineering.

[59]  K. Siebenrock,et al.  Long-term cell-mediated protein release from calcium phosphate ceramics. , 2009, Journal of biomedical materials research. Part A.

[60]  M. Schaffler,et al.  Prevention of fracture healing in rats by an inhibitor of angiogenesis. , 2001, Bone.

[61]  J. Schmitt,et al.  Bone morphogenetic proteins: An update on basic biology and clinical relevance , 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.